SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to its low float and potential for a short squeeze, with chatter highlighting AI/Robotics sympathy as a catalyst. Community members are actively discussing price targets, momentum trading strategies, and the possibility of a multi-day run. High volatility and cost to borrow are also fueling the speculative interest.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab ($RKLB) is trending amid excitement around a potential SpaceX IPO, which is driving speculation and interest in the broader space sector. The community is discussing Rocket Lab's potential for growth, Neutron rocket development, recent mission successes, and government contracts, as well as debating whether the stock is currently overvalued.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer's stock is trending due to upcoming 2026 guidance announcements and discussions around potential investment strategies, with some community members suggesting share buybacks or focusing on its pipeline. The stock's technicals and defensive qualities are also being debated, as is its potential in the weight loss drug market following recent deals. Community members are also actively discussing potential impacts on the company from recent reports related to COVID vaccines.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's stock is trending amid news of autonomous driving tests in Austin, fueling community excitement about robotaxi potential; some analysts are upgrading their price targets, while others express caution. Discussions revolve around the company's leadership in autonomy and AI, countered by concerns about valuation and competition. The stock's recent performance and high trading volume are also driving conversation.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is trending due to discussions surrounding its REZOLVE-AA Phase 2b study results for alopecia areata, with a focus on SALT score reductions and the drug's safety profile. Community sentiment is mixed, with some expressing concerns about statistical significance and potential outcomes, while others are optimistic about the upcoming conference call and potential buyout. The broader context involves comparisons to JAK inhibitors and anticipation of Phase 3 development in the treatment of severe-to-very-severe alopecia areata.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

NVTS is trending as investors discuss the stock's high short interest and potential for a squeeze, with some highlighting recent partnerships and long-term growth prospects in GaN technology. Community members are debating its valuation and relationship with NVDA, as well as its potential to capitalize on the growing AI data center market. Despite recent positive news, the stock's price action and trading volume are being closely watched for signs of a breakout.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the Platform and Devices segments. The Platform segment includes digital advertising and related services including the demand-side platform and content distribution services such as subscription and transaction revenue shares, media and entertainment promotional spending, the sale of premium subscriptions, and the sale of branded channel buttons on remote controls. The Devices segment is involved in the sale of streaming players, audio products, smart home products, and accessories that are sold through retailers and distributors, as well as directly to customers through the company’s website. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is trending due to an analyst upgrade from Morgan Stanley, citing a turning point in the ad cycle and increased confidence in margin expansion, sparking significant premarket activity. Community discussions revolve around the potential for a short squeeze and speculation on whether Roku can sustain gains above key price levels. Upgrades from other firms like Jefferies and JP Morgan are also boosting optimism around the company's growth prospects in connected TV advertising and platform revenue.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending due to discussions around AI infrastructure, potential hyperscaler deals (particularly with Microsoft), and reactions to recent price volatility. Community members are weighing the company's long-term potential against short-term market pressures, with some seeing current levels as a buying opportunity amid broader AI sector sentiment. Discussions also highlight the interplay between technical analysis, market sentiment, and the company's fundamental prospects in the data center space.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Inu ($SAILANA) is trending due to the anticipated launch of WolfSWAP this week, a cross-chain token-to-token swap platform. The community is highly bullish, anticipating significant utility and benefits for the memecoin space through WolfDAO and its treasury-funding mechanism. Many community members believe Sailana Inu has the potential for exponential growth, drawing comparisons to early Shiba Inu.

Tidal Trust II - YieldMax Ultra Option Income Strategy ETF

YieldMax Ultra Option Income Strategy ETF

ULTY is trending as investors discuss its high yield and weekly distributions amidst concerns about NAV erosion and potential reverse splits. The ETF's strategy and holdings are under scrutiny, with some community members questioning its long-term viability and others remaining optimistic about income generation. News articles and social media posts highlight both the potential risks and rewards of this ultra-high yield ETF.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Zen Upgrades Omeros (NASDAQ:OMER) to Hold

Wall Street Zen upgraded Omeros from a "sell" rating to a "hold" rating in a report on Saturday...

Omeros (NASDAQ:OMER) Trading Down 5.1% - Here's What Happened

Omeros (NASDAQ:OMER) Stock Price Down 5.1% - What's Next...

Omeros Corporation (NASDAQ:OMER) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Omeros Corporation (NASDAQ:OMER - Get Free Report) have received an average rating of "Moderate Buy" from the five research firms that are presently covering the firm, MarketBeat reports...

Omeros (NASDAQ:OMER) Stock Price Up 8.2% - Still a Buy?

Omeros (NASDAQ:OMER) Trading 8.2% Higher - What's Next...

Omeros (NASDAQ:OMER) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated a "buy" rating and set a $36.00 price objective on shares of Omeros in a research report on Monday...

<ul class="summary-bullets"><li>Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion.</li><li>The company retired its senior loan and expects the remaining cash to extend its runway.</li><li>Traders say the FDA decision on Narsoplimab is now the key market catalyst.</li></ul><p>Omeros Corporation&nbsp;(OMER) said on Monday it has completed its asset sale and licensing agreement with Novo Nordisk for Zaltenibart, an experimental drug being developed for rare immune-related blood and kidney disorders. The transaction includes up to $2.1 billion in potential payments.</p><p>OMER stock traded in the green at the time of writing.&nbsp;</p><h2 class="st-heading-2"><strong>Terms Of The Deal</strong></h2><p>Omeros received $240 million upfront at closing and could earn up to $340 million in early milestones. The agreement grants Novo Nordisk global rights to Zaltenibart and its intellectual property, with total potential value reaching $2.1 billion through future development and commercial milestones. Omeros will also receive tiered royalties on net sales.</p><h2 class="st-heading-2"><strong>Immune Drug Targets Severe Rare Diseases</strong></h2><p>Zaltenibart, formerly OMS906, is a clinical-stage monoclonal antibody that blocks MASP-3, the immune trigger that switches on the alternative complement pathway. The drug is designed to calm an overactive immune response while preserving the body’s main infection-fighting mechanisms. Potential applications include paroxysmal nocturnal hemoglobinuria and several complement-driven kidney disorders. Novo Nordisk said the acquisition strengthens its position in rare immunological diseases.</p><h2 class="st-heading-2"><strong>Upfront Proceeds Slash Debt And Extend Cash Runway</strong></h2><p>Omeros used part of the upfront payment to fully repay its $67.1 million senior secured term loan, including premiums and interest, resulting in the release of all related covenants. The company expects remaining proceeds to cover repayment of its $17.1 million 2026 Convertible Notes and fund more than a year of operations, including preparations for a potential U.S. launch of its MASP-2 inhibitor Narsoplimab. The company continues to advance additional complement-system candidates, including OMS1029 and OMS527.</p><h2 class="st-heading-2"><strong>Stocktwits Users Warn Of FDA-Driven Swings</strong></h2><p>On Stocktwits, Omeros drew ‘bullish’ retail sentiment with ‘normal’ message volume, while Novo Nordisk saw ‘bearish’ sentiment on ‘low’ volume.</p><figure class="image"><img style="aspect-ratio:971/144;" src="https://news.stocktwits-cdn.com/omer_ss_png_4011ca93db.webp" alt="omer ss.png" width="971" height="144"><figcaption>OMER sentiment and message volume as of December 1| Source: Stocktwits</figcaption></figure><figure class="image"><img style="aspect-ratio:970/144;" src="https://news.stocktwits-cdn.com/nvo_ss_png_d0f2e79132.webp" alt="nvo ss.png" width="970" height="144"><figcaption>NVO sentiment and message volume as of December 1| Source: Stocktwits</figcaption></figure><p>One user noted that the announcement appeared mostly priced in around $10 and said the stock now hinges on a potential FDA approval for Zaltenibart due Dec.26, calling it a "pure binary event" that could swing shares 30%–50% either way over the next few weeks.</p><p><stembedurl>https://stocktwits.com/WinstonWolfff/message/637795055</stembedurl></p><p>Another user said, “This deal was known for a long time already. What did you expect? Narsoplimabs FDA approval this month is the moneyball.”&nbsp;</p><p><stembedurl>https://stocktwits.com/Iceman89/message/637792822</stembedurl></p><p><a href="https://stocktwits.com/symbol/OMER">Omeros’ stock</a> has declined nearly 2% so far in 2025, while&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s U.S.-listed stock</a> fell about 42% over the same period.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call

Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion.

Equity

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906...

Omeros (NASDAQ:OMER) Shares Pass Above 200 Day Moving Average - Here's Why

Omeros (NASDAQ:OMER) Stock Price Crosses Above 200 Day Moving Average - Here's What Happened...

Omeros (NASDAQ:OMER) Shares Down 5.6% - Should You Sell?

Omeros (NASDAQ:OMER) Shares Down 5.6% - Here's What Happened...

Omeros (NASDAQ:OMER) Stock Price Up 8.1% - Time to Buy?

Omeros (NASDAQ:OMER) Shares Up 8.1% - Here's What Happened...

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.52	--	--	N/A
Q3 '25	-$0.45	-$0.47	-5.19%	MISSED
Q2 '25	-$0.50	-$0.43	14.47%	BEAT
Q1 '25	-$0.57	-$0.58	-2.50%	MISSED
Q4 '24	-$0.78	-$0.54	30.37%	BEAT

OMER
Omeros Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest OMER News

OMEROmeros Corp